Vanderbilt Human Research Protection Program
Institutional Biosafety Committee-Human Subjects
NIH Registration Number TN00040
The IBC-HS Committee meets the third Friday of the month from 8:30 to 10:30 am. Meeting locations are subject to change. Please call the VHRPP office to confirm meeting location (322-2918).
Effective – July 1, 2021
VOTING MEMBERS (10)
Antonis Hatzopoulos, PhD - Chair
Allison Wheeler, MD - Vice-Chair
Stephen Brandt, MD
Jonathan Lehman, MD, PhD
Douglas Johnson, MD
Lori Rolando, MD, MPH
Richard DiTullio, PhD
Donna Torr, PharmD
Kimberly Towers
Rolanda Edding, MT(ASCP)
Cell and Developmental Biology
Pulmonary/Critical Care
Hematology/Oncology
Hematology/Oncology
Hematology/Oncology
Occupational Health and Safety
Biological Safety Officer
Investigational Drug Service
Community Member
Community Member/Department of Health
ALTERNATE MEMBERS
Ray Peebles, MD Pathology/Pediatric Oncology
Carrie Kitko, MD Pediatric Stem Cell Transplantation
Jennifer Bounds, Community Member
Brenton Harrison, Community Member
Vanderbilt’s Institutional Biosafety Committee-Human Subjects (IBC-HS) is authorized by the National Institutes of Health (NIH) to approve research projects involving the use of recombinant DNA and synthetic nucleotide research involving humans. Use the IBC application that is embedded in the IRB application and guidelines to submit proposals to the IBC-HS. If you need help in completing and IBC-HS application, contact the IRB to have the a member of the IBC-HS team to assist you.